Artal Group S.A. Aptinyx Inc. Transaction History

Artal Group S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	BUY	$2.86 - $4.33 $10.3 Million - $15.7 Million	3,614,458 Added 144.46%	6,116,493 $18.3 Million
Q4 2020 Feb 11, 2021	BUY	$2.93 - $4.3 $2.93 Million - $4.3 Million	1,000,000 Added 66.58%	2,502,035 $8.66 Million
Q3 2020 Nov 13, 2020	SELL	$3.05 - $4.99 $241,117 - $394,484	-79,055 Reduced 5.0%	1,502,035 $5.08 Million
Q2 2020 Aug 14, 2020	SELL	$1.99 - $4.4 $170,296 - $376,534	-85,576 Reduced 5.13%	1,581,090 $6.59 Million
Q1 2020 May 14, 2020	BUY	$1.81 - $5.03 $3.02 Million - $8.38 Million	1,666,666 New	1,666,666 $3.6 Million

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.